The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Abstract The neoadjuvant and adjuvant anti-PD-1/PD-L1 treatment has been increasingly noticed. To summarize the global landscape of these clinical trials will provide essential data for all the stakeholders of drug development. Based on the Trialtrove database, a total of 668 clinical trials initiat...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-02-01
|
| Series: | Journal of Hematology & Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13045-022-01227-1 |
| _version_ | 1818977134165622784 |
|---|---|
| author | Dawei Wu Huiyao Huang Minghui Zhang Ziwei Li Shuhang Wang Yue Yu Yuan Fang Ning Jiang Huilei Miao Peiwen Ma Yu Tang Ning Li |
| author_facet | Dawei Wu Huiyao Huang Minghui Zhang Ziwei Li Shuhang Wang Yue Yu Yuan Fang Ning Jiang Huilei Miao Peiwen Ma Yu Tang Ning Li |
| author_sort | Dawei Wu |
| collection | DOAJ |
| description | Abstract The neoadjuvant and adjuvant anti-PD-1/PD-L1 treatment has been increasingly noticed. To summarize the global landscape of these clinical trials will provide essential data for all the stakeholders of drug development. Based on the Trialtrove database, a total of 668 clinical trials initiated by the end of 2020 were retrospectively analyzed. We found that a rising capability of global neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical development has been achieved. High prevalent cancer types were extensively studied though the priorities in China and the United States were different. However, a lack of phase III trials and industry-sponsored trials was addressed. The confirmatory neoadjuvant trials were particularly insufficient, and the combination strategy mainly focused on chemotherapy. Thus, more public funding and accelerated regulatory strategies are needed in this field. Efforts should be made to confirm the benefit of neoadjuvant treatment and explore novel combination strategies. |
| first_indexed | 2024-12-20T16:22:54Z |
| format | Article |
| id | doaj.art-11990d94452e40599aebebaa00007503 |
| institution | Directory Open Access Journal |
| issn | 1756-8722 |
| language | English |
| last_indexed | 2024-12-20T16:22:54Z |
| publishDate | 2022-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Hematology & Oncology |
| spelling | doaj.art-11990d94452e40599aebebaa000075032022-12-21T19:33:33ZengBMCJournal of Hematology & Oncology1756-87222022-02-011511410.1186/s13045-022-01227-1The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trialsDawei Wu0Huiyao Huang1Minghui Zhang2Ziwei Li3Shuhang Wang4Yue Yu5Yuan Fang6Ning Jiang7Huilei Miao8Peiwen Ma9Yu Tang10Ning Li11Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeClinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Medical Oncology, Harbin Medical University Cancer HospitalClinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeClinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeClinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeClinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeClinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeClinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeClinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeClinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeClinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeAbstract The neoadjuvant and adjuvant anti-PD-1/PD-L1 treatment has been increasingly noticed. To summarize the global landscape of these clinical trials will provide essential data for all the stakeholders of drug development. Based on the Trialtrove database, a total of 668 clinical trials initiated by the end of 2020 were retrospectively analyzed. We found that a rising capability of global neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical development has been achieved. High prevalent cancer types were extensively studied though the priorities in China and the United States were different. However, a lack of phase III trials and industry-sponsored trials was addressed. The confirmatory neoadjuvant trials were particularly insufficient, and the combination strategy mainly focused on chemotherapy. Thus, more public funding and accelerated regulatory strategies are needed in this field. Efforts should be made to confirm the benefit of neoadjuvant treatment and explore novel combination strategies.https://doi.org/10.1186/s13045-022-01227-1NeoadjuvantAdjuvantAnti-PD-1/PD-L1 treatmentClinical trial |
| spellingShingle | Dawei Wu Huiyao Huang Minghui Zhang Ziwei Li Shuhang Wang Yue Yu Yuan Fang Ning Jiang Huilei Miao Peiwen Ma Yu Tang Ning Li The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials Journal of Hematology & Oncology Neoadjuvant Adjuvant Anti-PD-1/PD-L1 treatment Clinical trial |
| title | The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials |
| title_full | The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials |
| title_fullStr | The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials |
| title_full_unstemmed | The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials |
| title_short | The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials |
| title_sort | global landscape of neoadjuvant and adjuvant anti pd 1 pd l1 clinical trials |
| topic | Neoadjuvant Adjuvant Anti-PD-1/PD-L1 treatment Clinical trial |
| url | https://doi.org/10.1186/s13045-022-01227-1 |
| work_keys_str_mv | AT daweiwu thegloballandscapeofneoadjuvantandadjuvantantipd1pdl1clinicaltrials AT huiyaohuang thegloballandscapeofneoadjuvantandadjuvantantipd1pdl1clinicaltrials AT minghuizhang thegloballandscapeofneoadjuvantandadjuvantantipd1pdl1clinicaltrials AT ziweili thegloballandscapeofneoadjuvantandadjuvantantipd1pdl1clinicaltrials AT shuhangwang thegloballandscapeofneoadjuvantandadjuvantantipd1pdl1clinicaltrials AT yueyu thegloballandscapeofneoadjuvantandadjuvantantipd1pdl1clinicaltrials AT yuanfang thegloballandscapeofneoadjuvantandadjuvantantipd1pdl1clinicaltrials AT ningjiang thegloballandscapeofneoadjuvantandadjuvantantipd1pdl1clinicaltrials AT huileimiao thegloballandscapeofneoadjuvantandadjuvantantipd1pdl1clinicaltrials AT peiwenma thegloballandscapeofneoadjuvantandadjuvantantipd1pdl1clinicaltrials AT yutang thegloballandscapeofneoadjuvantandadjuvantantipd1pdl1clinicaltrials AT ningli thegloballandscapeofneoadjuvantandadjuvantantipd1pdl1clinicaltrials AT daweiwu globallandscapeofneoadjuvantandadjuvantantipd1pdl1clinicaltrials AT huiyaohuang globallandscapeofneoadjuvantandadjuvantantipd1pdl1clinicaltrials AT minghuizhang globallandscapeofneoadjuvantandadjuvantantipd1pdl1clinicaltrials AT ziweili globallandscapeofneoadjuvantandadjuvantantipd1pdl1clinicaltrials AT shuhangwang globallandscapeofneoadjuvantandadjuvantantipd1pdl1clinicaltrials AT yueyu globallandscapeofneoadjuvantandadjuvantantipd1pdl1clinicaltrials AT yuanfang globallandscapeofneoadjuvantandadjuvantantipd1pdl1clinicaltrials AT ningjiang globallandscapeofneoadjuvantandadjuvantantipd1pdl1clinicaltrials AT huileimiao globallandscapeofneoadjuvantandadjuvantantipd1pdl1clinicaltrials AT peiwenma globallandscapeofneoadjuvantandadjuvantantipd1pdl1clinicaltrials AT yutang globallandscapeofneoadjuvantandadjuvantantipd1pdl1clinicaltrials AT ningli globallandscapeofneoadjuvantandadjuvantantipd1pdl1clinicaltrials |